ICON-PLC Launches New Medical Imaging Solution for Early Phase Trials
Published: Oct 17, 2012
This new solution incorporates streamlined processes and procedures to maximise the information collected from image data and to ensure that this information is processed rapidly in line with the shorter timelines and requirements of early-phase research. Enhanced decision making is then enabled by MIRA™, ICON’s image management system, which standardises data from all imaging formats and allows for centralised analysis and interpretation of data. Driving this innovation is a team of scientific and regulatory experts with deep imaging and early-phase experience to help sponsors make critical decisions about their compounds faster.
“PET, volumetrics, advanced CT and MRI are increasingly being used in early phase research which has created a demand for more tailored imaging solutions for early phase trials,” commented Ted Gastineau, President, ICON Medical Imaging. “We have developed a unique and cost-effective solution that provides true insight to the data generated from imaging technologies and helps clients decide earlier about the future success of a drug.”
ICON Medical Imaging’s early phase group will be led by Dr. James Conklin, Senior Vice President, Medical and Scientific Affairs and Dr. Valerie Treyer, Director, Medical and Scientific Affairs, who together bring over 45 years of experience in the management of medical image data used in clinical trials. The group will work closely with ICON Development Solutions which provides a full range of early-phase services, including clinical pharmacology, bioanalytical, PK/PD modelling and simulation, and Clinical Pharmacodynamic Models for early indications of drug efficacy.
About ICON plc
ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. ICON currently has over 9,200 employees, operating from 82 locations in 40 countries.
Tel: +44 0207 067 0594